01 — At a Glance
The Seed Company That Grows When Everything Else Stops
- 52-Week High / Low₹1,602 / ₹705
- TTM Revenue₹1,378 Cr
- TTM PAT (Full Year)₹301 Cr
- Full-Year EPS (TTM)₹58.5
- 9M FY26 Revenue₹1,221.56 Cr
- Book Value₹349
- Price to Book2.31x
- Dividend Yield0.63%
- Debt / Equity0.00x
- ROE (3-Year Avg)18.5%
The Opening Statement: Kaveri Seed Company closed 9MFY26 with ₹1,221.56 crore revenue (+16.94% YoY). Maize is up 21% in volume, non-cotton seeds are printing money (+13% realization growth), and cotton—bless it—is still getting murdered by illegal HT hybrids. Stock crashed 30.5% in one year. But somehow the company posted 5-year ROE at 19.1%. That’s the market saying “Your fundamentals are strong, but we’re offended by your business model anyway.”
02 — Introduction
Let’s Talk About The Unglamorous Hero Nobody Talks About
Kaveri Seed Company doesn’t have a metaverse. No AI. No blockchain. No “synergistic digital transformation narrative.” What it has is: seeds. Hybrid seeds. For crops. That farmers plant in dirt.
And yet, if you want to eat rice, maize, cotton, or okra, someone—somewhere in India’s agriculture supply chain—bought from Kaveri’s 3,785-strong distributor network. The company plants research in 12 agro-climatic zones, breeds hybrids that survive monsoon tantrums, and somehow manages 51% hybrid rice market share in half of India.
The stock got hammered 30.5% in the last 12 months. Why? Because every growth quarter comes with: (a) management saying “margins got squeezed by cost of production,” and (b) the market interpreting this as “Oh, they’re doomed.” Ignore the 20% ROCE. Ignore the 6.52% R&D spend (₹73 crores annually). Ignore that exports jumped 86% YoY. The narrative wins.
Then there’s the income tax demand of ₹69.58 crores from March 2025—which the company calmly noted as “we’re appealing” and moved on. That’s ₹126 crores in combined tax demands since April 2024. And the company? Building 100% subsidiaries in Bangladesh. Acquiring 30% of Aditya Agritech. Pumping 64 crores into R&D infrastructure. The audacity of hope, apparently, is farming-related.
Concall Reality (Feb 2026): When asked about margins, management said: “the cost of production is a bit high… we were not able to pass it on to the farmer this time.” Translation: We could’ve, but we chose to eat the margin to gain volume. That’s called a strategic decision, but market calls it “being bad at pricing power.”
03 — Business Model: WTF Do They Even Do?
Breeding, Selling, Exporting. Rinse. Repeat. Since 1976.
Kaveri Seed Company takes this approach: find superior crop genetics, breed them in 750 acres of R&D farms, test in 12 agro-climatic zones, get farmer approval, mass-produce at 9 manufacturing plants, and sell through 3,785 distributors and 65,000+ retailers. Simple. Boring. Effective.
The product portfolio is relentlessly practical: Cotton (28% of revenue), Hybrid Rice (24%), Maize (25%), Selection Rice (16%), Vegetables (4%), and others (3%). No product has fewer than a dozen research hybrids competing internally. Quality control? 750 acres of breeding farms. That’s not a cute hobby garden—that’s agro-research at scale.
The company has collaborations with IRRI (Philippines), CIMMYT (Mexico), ICRISAT (India), INRAE (France). This is basically saying: “We’ve built a network of global seed genetics so advanced that even if our competitors copy us, we’re already three monsoons ahead.”
Export business grew 86% in Q3 alone (₹180 crores annually at current run rate). Markets: Bangladesh, Vietnam, Laos, Cambodia, Nepal, Philippines, UAE, Tanzania, Algeria. The company says “we work on LCs, we don’t give credit.” No nightmares of non-payment from Tanzanian farmers. Very adult of them.
Cotton28%Revenue Share
Maize25%Revenue Share
H-Rice24%Revenue Share
S-Rice16%Revenue Share
Inventory Note: Maize inventory ballooned post-last-year’s demand spike. Everyone flooded the market. Prices crashed. Kaveri couldn’t pass cost on to farmers (they said so on the concall). So they ate it, gained volume, and are now waiting for the market to “normalize.” That’s faith in your own product reliability, disguised as margin compression.
💬 Ever bought seeds from a local retailer? Ever wonder who bred them? (Spoiler: Probably Kaveri, if it’s a hybrid rice or maize seed in India.)
04 — Financials Overview
Q3 FY26: The Numbers That Don’t Match The Stock Price
Result type: Quarterly Results | Q3 FY26 EPS: ₹2.53 (annualised: ₹10.12) | 9M FY26 Revenue: ₹1,221.56 Cr (+16.94% YoY)
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 173.65 | 154.77 | 219.07 | +16.08% | -20.66% |
| Operating Profit | 25.38 | 25.09 | 60.39 | +1.14% | -57.98% |
| OPM % | 14.6% | 16.2% | 27.5% | -160 bps | -1290 bps |
| PAT | 7.46 | 8.66 | 18.81 | -13.75% | -60.34% |
| EPS (₹) | 2.53 | 2.94 | 6.37 | -13.95% | -60.28% |
The Reality Check: Q3 revenue up 16%. OPM down 160 bps YoY. PAT down 14% YoY. This is the classic “we’re growing topline while profit margins compress” story. Per the Feb 2026 concall, management blamed it on: (a) maize cost of production being high, (b) industry oversupply (everyone dumped inventory), and (c) farmers having weak rabi pricing power. Their own words: “we were not able to pass it on to the farmer this time.” But here’s the thing—they expect it to normalize to the 45–48% gross margin band they’ve historically held. That’s faith, or optimism, or both.
05 — Valuation: Fair Value Range
What Is A Company That Grows Crops Really Worth?
Method 1: P/E Based
TTM EPS = ₹58.5. Current P/E = 13.8x. Sector median = 24.6x. Kaveri’s justified multiple (given 20% ROCE, 19% ROE, but margin volatility): 1.0x–1.3x sector median = 24.6x–32x. But given near-term margin pressure, apply conservative 0.9x–1.2x = 22.1x–29.5x.
Range: ₹1,292 – ₹1,725
Method 2: EV/EBITDA Based
TTM EBITDA = ₹410 Cr (approx, derived from OPM 24% on TTM revenue ₹1,378 Cr). Current EV = ₹4,135 Cr (market cap minus negligible net cash). EV/EBITDA = 10.1x. Pharma/agri-peers trade 10x–14x. Kaveri justified: 10.5x–12x given ROCE and ROE quality.
EV range (10.5x–12x): ₹4,305 Cr – ₹4,920 Cr → Per share (5.13Cr shares):
Range: ₹839 – ₹958
Method 3: DCF Based
Base FCFF: ₹385 Cr (approx). Growth: 10–12% for 5 years (reversion to 45–48% margin band; cost normalization). Terminal growth: 4%. WACC: 10%.
→ PV of 5-year FCFFs at 10%: ~₹2,350 Cr
→ Terminal Value (4% growth / 6% cap rate): ~₹3,560 Cr
→ Total EV: ~₹5,910 Cr (negligible debt)
Range: ₹1,151 – ₹1,410
Fair Min: ₹850
CMP: ₹806 | One Year Back: ₹1,150
Fair Max: ₹1,400
CMP ₹806 (Oversold?)
One Year Ago ₹1,150
⚠️ EduInvesting Fair Value Range: ₹850 – ₹1,400. CMP ₹806 sits below the fair range. The -30% crash has created a valuation discount. This fair value range is for educational purposes only and is not investment advice. Please consult a SEBI-registered investment advisor before making any financial decision.
06 — What’s Cooking: News, Triggers & Chaos
The Seed Company’s Soap Opera, Quietly
